Resources & Support

Detect drug induced liver injury (DILI) early in the drug discovery process with 爱游戏平台注册登录 's IVISense^™ Toxicology Fluorescent Imaging Panel.

Drug-induced liver injury (DILI) is the leading reason for termination of drug discovery research projects and is a significant concern in attrition of new drug molecules reaching phase III clinical trials. DILI can manifest in hepatocellular, cholestatic, and steatotic forms differing in the type and pattern of tissue injury, biomarker expression and inflammation in the liver lobules.

For research use only. Not for use in diagnostic procedures.